Alumis (ALMS) Financials

Alumis (NASDAQ:ALMS) remains well-capitalized but continues to face substantial operating losses. The company ended the second quarter of 2026 with $63.7 million in cash and equivalents and $438.6 million in short-term investments, providing significant liquidity. However, revenue remains modest and has generally declined since the first quarter of 2025, while research and development spending continues to drive large cash losses.

• Strong liquidity position: Cash and short-term investments totaled approximately $502.3 million at June 30, 2026. Total current assets of $514.1 million were roughly 6.7 times total current liabilities of $76.2 million, indicating substantial near-term financial flexibility.
• Limited balance-sheet leverage: Total liabilities were $108.5 million compared with $452.2 million of equity. The provided statements do not show significant traditional debt, reducing interest-rate and refinancing risk.
• Investment income provides some support: Interest and investment income was $4.9 million in the second quarter of 2026, helping offset a portion of the company’s operating expenses and reflecting the benefit of its large investment portfolio.
• Quarterly cash decline was nearly flat: Net cash decreased by only $179,000 in Q2 2026, compared with a $25.8 million decline in Q1. This improvement was primarily supported by $108.6 million of investment sales or maturities and $12.6 million of financing inflows.
• Liquidity runway appears meaningful but depends on continued spending: Q2 operating cash outflow was $81.5 million. A simple comparison of approximately $502 million in cash and short-term investments with that quarterly burn suggests several quarters of funding, although actual runway will depend on clinical spending, investment activity, financing, and changes in working capital.
• Revenue is present but not yet a meaningful offset to expenses: Q2 2026 revenue was $1.7 million, down from $1.9 million in Q4 2025 and $2.7 million in Q2 2025. The company’s current financial profile remains driven primarily by development activities rather than commercial revenue.
• Operating losses remain substantial: Net loss widened to $142.2 million in Q2 2026 from $93.1 million in Q1 and $92.9 million in Q4 2025. The second-quarter loss included a $41.8 million impairment charge, but the company still recorded an operating loss of $107.1 million excluding that charge.
• Research and development spending continues to consume capital: R&D expense increased to $85.3 million in Q2 2026 from $81.5 million in Q1. SG&A also rose to $23.4 million, contributing to total operating expenses of $150.5 million.
• Operating cash burn has persisted for multiple years: Alumis reported negative operating cash flow in every listed quarter from Q3 2023 through Q2 2026. Q2 2026 operating cash outflow of $81.5 million improved from $87.1 million in Q1 but remained well above the company’s revenue generation.
• Share dilution is an ongoing risk: Weighted-average basic shares increased to 127.7 million in Q2 2026 from 125.1 million in Q1 and 85.0 million in Q4 2025. The company also raised $323.8 million through common equity issuance in Q1 2026, which strengthened liquidity but diluted existing shareholders.

Overall, Alumis has a sizeable cash and investment cushion and a relatively modest liability balance, which reduces immediate financing pressure. The more important risks are continued clinical-development spending, recurring operating cash burn, weak revenue growth, impairment charges, and additional equity issuance. Investors should also treat the unusually strong $59.3 million net income reported in Q2 2025 cautiously, as it was driven largely by a $187.9 million gain recorded in other income and does not appear representative of the company’s underlying operating performance.